NDMA OPPOSES REQUIRING COMPARATIVE STUDIES WITH CURRENT OTCs
This article was originally published in The Tan Sheet
Executive Summary
NDMA OPPOSES REQUIRING COMPARATIVE STUDIES WITH CURRENT OTCs as the basis for determining the efficacy of a new OTC analgesic, Nonprescription Drug Manufacturers Association Senior VP/Director- Science and Technology William Soller, PhD, said in a Sept. 9 presentation to the FDA subcommittee on analgesics. NDMA believes that the current FDA policy for approving OTC candidates is adequate, Soller said.